Abstract
There are over 210,000 mitral valve operations performed in the United States every year with over 50 % of these patients undergoing mitral valve replacement. Despite shorter durability compared to mechanical valves, bioprosthetic valve usage has continued to rise. This is related to advancements in surgical valve technology, patient preference, and avoidance of long-term anticoagulation [1]. Bioprosthetic structural valve degeneration (SVD) can overtime lead to valvular regurgitation, stenosis, or mixed pathology. It occurs via a variety of mechanisms including leaflet perforation, leaflet tears, commissural tears, cuspal detachment, and restricted leaflet motion. Leaflet dysfunction is most commonly related to collagen degeneration and dystrophic calcification within the bioprosthetic tissue. The true incidence of bioprosthetic valve failure is likely underreported in the published literature and varies greatly between studies. In general, younger patients (less than 65 years of age) have much higher rates of SVD compared to their older counterparts and reoperation more frequently. A number of publications have done subgroup analysis to determine the effect of age at time of surgical mitral valve replacement on the rate of SVD. Table 18.1 shows the differences of published rates of SVD based on age at time of valve implantation. Although older patients have lower rates of SVD compared to their younger counterparts, it still occurs at relatively high frequency. These high rates of SVD in combination with good long-term survival after initial mitral valve surgery has led to increasing numbers of patients requiring reoperations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009;87(5):1431–7.
Borger MA, Ivanov J, Armstrong S, Christie-hrybinsky D, Feindel CM, David TE. Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis. 2006;15(1):49–55.
Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36(4):1152–8.
Bourguignon T, Bouquiaux-stablo AL, Loardi C, et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg. 2014;148(5):2004–2011.e1.
Jamieson WR, Von Lipinski O, Miyagishima RT, et al. Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement. J Thorac Cardiovasc Surg. 2005;129(6):1301–8.
Ruel M, Chan V, Bédard P, et al. Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age. Circulation. 2007;116(11 Suppl):I294–300.
Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014;147(1):117–26.
Jamieson WR, Gudas VM, Burr LH, et al. Mitral valve disease: if the mitral valve is not reparable/failed repair, is bioprosthesis suitable for replacement? Eur J Cardiothorac Surg. 2009;35(1):104–10.
Mykén PS. Seventeen-year experience with the St. Jude medical biocor porcine bioprosthesis. J Heart Valve Dis. 2005;14(4):486–92.
Chan V, Malas T, Lapierre H, et al. Reoperation of left heart valve bioprostheses according to age at implantation. Circulation. 2011;124(11 Suppl):S75–80.
Potter DD, Sundt TM, Zehr KJ, et al. Risk of repeat mitral valve replacement for failed mitral valve prostheses. Ann Thorac Surg. 2004;78(1):67–72.
Fukunaga N, Okada Y, Konishi Y, et al. Clinical outcomes of redo valvular operations: a 20-year experience. Ann Thorac Surg. 2012;94(6):2011–6.
Jamieson WR, Burr LH, Miyagishima RT, et al. Reoperation for bioprosthetic mitral structural failure: risk assessment. Circulation. 2003;108 Suppl 1:II98–102.
Balsam LB, Grossi EA, Greenhouse DG, et al. Reoperative valve surgery in the elderly: predictors of risk and long-term survival. Ann Thorac Surg. 2010;90(4):1195–200.
Kirsch M, Nakashima K, Kubota S, Houël R, Hillion ML, Loisance D. The risk of reoperative heart valve procedures in Octogenarian patients. J Heart Valve Dis. 2004;13(6):991–6.
Jones JM, O'kane H, Gladstone DJ, et al. Repeat heart valve surgery: risk factors for operative mortality. J Thorac Cardiovasc Surg. 2001;122(5):913–8.
Dvir, D. (2014, September 14th). Perspectives from Valve-in-Valve Experiences. TCT 2014, Washington DC.
Bapat VN, Attia RQ, Condemi F, et al. Fluoroscopic guide to an ideal implant position for Sapien XT and CoreValve during a valve-in-valve procedure. JACC Cardiovasc Interv. 2013;6(11):1186–94.
Bapat VN, Attia R, Thomas M. Effect of valve design on the stent internal diameter of a bioprosthetic valve: a concept of true internal diameter and its implications for the valve-in-valve procedure. JACC Cardiovasc Interv. 2014;7(2):115–27.
Cullen MW, Cabalka AK, Alli OO, et al. Transvenous, antegrade Melody valve-in-valve implantation for bioprosthetic mitral and tricuspid valve dysfunction: a case series in children and adults. JACC Cardiovasc Interv. 2013;6(6):598–605.
Gaia DF, Breda JR, Ferreira CB, De Souza JA, Buffolo E, Palma JH. Double transapical aortic and mitral valve-in-valve implant: an alternative for high risk and multiple reoperative patients. Int J Cardiol. 2013;164(3):e32–4.
Gaia DF, Palma JH. De souza JA, et al. Transapical mitral valve-in-valve implant: an alternative for high risk and multiple reoperative rheumatic patients. Int J Cardiol. 2012;154(1):e6–7.
Bapat V, Adams B, Attia R, Noorani A, Thomas M. Neo-annulus: A reference plane in a surgical heart valve to facilitate a valve-in-valve procedure. Catheter Cardiovasc Interv. 2014.
Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014;148(1):e1–132.
Cheung A, Webb JG, Barbanti M, et al. 5-year experience with transcatheter transapical mitral valve-in-valve implantation for bioprosthetic valve dysfunction. J Am Coll Cardiol. 2013;61(17):1759–66.
Raval J, Nagaraja V, Eslick GD, Denniss AR. Transcatheter valve-in-valve implantation: a systematic review of literature. Heart Lung Circ. 2014;23(11):1020–8.
Seeburger J, Borger MA, Falk V, et al. Minimal invasive mitral valve repair for mitral regurgitation: results of 1339 consecutive patients. Eur J Cardiothorac Surg. 2008;34(4):760–5.
David TE, Armstrong S, Mccrindle BW, Manlhiot C. Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation. 2013;127(14):1485–92.
Flameng W, Herijgers P, Bogaerts K. Recurrence of mitral valve regurgitation after mitral valve repair in degenerative valve disease. Circulation. 2003;107(12):1609–13.
De Weger A, Ewe SH, Delgado V, Bax JJ. First-in-man implantation of a trans-catheter aortic valve in a mitral annuloplasty ring: novel treatment modality for failed mitral valve repair. Eur J Cardiothorac Surg. 2011;39(6):1054–6.
Descoutures F, Himbert D, Maisano F, et al. Transcatheter valve-in-ring implantation after failure of surgical mitral repair. Eur J Cardiothorac Surg. 2013;44(1):e8–15.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Morse, M.A., Meece, R., Rodriguez, E. (2016). Mitral Valve. In: Ailawadi, G., Kron, I. (eds) Catheter Based Valve and Aortic Surgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3432-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3432-4_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3430-0
Online ISBN: 978-1-4939-3432-4
eBook Packages: MedicineMedicine (R0)